Apis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPH

Key Points

• Apis Capital Advisors LLC increased its stake in scPharmaceuticals by 28.2% in Q1, holding approximately 1.00% of the company, valued at $1.33 million.
• Several analysts have recently downgraded scPharmaceuticals, with a consensus rating of "Hold" and a target price of $12.00.
• scPharmaceuticals reported a quarterly EPS of ($0.34), missing estimates, although it exceeded revenue expectations with $16.04 million for the period.

Apis Capital Advisors LLC lifted its position in shares of scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report) by 28.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 504,947 shares of the company's stock after buying an additional 110,947 shares during the quarter. Apis Capital Advisors LLC owned approximately 1.00% of scPharmaceuticals worth $1,328,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Chicago Partners Investment Group LLC acquired a new stake in scPharmaceuticals during the first quarter worth approximately $31,000. Assenagon Asset Management S.A. acquired a new stake in shares of scPharmaceuticals during the first quarter worth $33,000. Legato Capital Management LLC grew its position in shares of scPharmaceuticals by 48.1% in the first quarter. Legato Capital Management LLC now owns 15,275 shares of the company's stock valued at $40,000 after purchasing an additional 4,961 shares during the period. Perkins Capital Management Inc. increased its stake in scPharmaceuticals by 41.0% in the first quarter. Perkins Capital Management Inc. now owns 17,200 shares of the company's stock valued at $45,000 after purchasing an additional 5,000 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in scPharmaceuticals during the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 89.52% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on SCPH. Wall Street Zen upgraded scPharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Maxim Group downgraded shares of scPharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, August 25th. HC Wainwright cut shares of scPharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday. Finally, Craig Hallum downgraded scPharmaceuticals from a "buy" rating to a "hold" rating and set a $6.00 price objective for the company. in a report on Monday, August 25th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, scPharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $12.00.

scPharmaceuticals Stock Performance

NASDAQ:SCPH opened at $5.50 on Friday. The firm's fifty day simple moving average is $4.75 and its 200 day simple moving average is $3.65. The company has a current ratio of 3.85, a quick ratio of 3.14 and a debt-to-equity ratio of 3.86. scPharmaceuticals, Inc. has a twelve month low of $1.94 and a twelve month high of $6.28. The firm has a market capitalization of $293.15 million, a price-to-earnings ratio of -3.04 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The company had revenue of $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative return on equity of 1,647.86%. As a group, equities research analysts expect that scPharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Want to see what other hedge funds are holding SCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for scPharmaceuticals, Inc. (NASDAQ:SCPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.